Fujirebio Europe upgrades its HPV (Human Papillomavirus) genotyping panel with the launch of the INNO-LiPA® HPV Genotyping Extra II assay

Product news

Gent, Belgium: March 5, 2015 - Fujirebio Europe today announced the release of the INNO-LiPA® HPV Genotyping Extra II assay for HPV type-specific patient monitoring and cervical cancer management. This CE-marked strip-based assay is available for automated testing on the Auto-LiPA™ 48 and AutoBlot 3000H platforms and the upcoming TENDIGO™ platform as well as for manual testing.

“With this upgrade of the existing INNO-LiPA® HPV Genotyping Extra test Fujirebio Europe continues to confirm its position as one of the world leaders in strip-based diagnostic solutions,” said Christiaan De Wilde, CEO at Fujirebio Europe. Cervical cancer is the 2nd most common cancer among women worldwide, and HPV infection is one of the central causes of cervical cancer. HPV genotyping is therefore a part of good gynecological care and is also an important and reliable diagnostic tool for successful management of patients infected with HPV,” said Geert Jannes, Principal Scientist at Fujirebio Europe. “Our new INNO-LiPA® HPV Genotyping Extra II test provides maximal HPV type-specific information to clinicians and patients allowing an optimal and complete clinical follow up.”

The new INNO-LiPA® HPV Genotyping Extra II assay has an extended typing capability of 32 HPV genotypes, including 13 High Risk (HR) genotypes and 6 potential HR types. The new kit has converted to full genotype specific probes, an upgraded primer set resulting in improved sensitivity (comparable for all HR genotypes), and provides a ready-to-use amplification reagent.

Please contact your local sales representative for the availability of these products in your country. This product is not available in the USA and in Canada.

About Fujirebio

Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostic solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries.